Researchers from the Oxford Precision Psychiatry Lab responded to COVID-19 by creating vital evidence-based guidance for patients and clinicians managing mental health conditions during the pandemic.
Frequently updated, this guidance summarises the best available clinical guidelines about key COVID-19 questions that are faced by frontline mental health professionals every day.
Designed for busy clinicians and organised around specific clinical questions the guidance is derived from existing guidelines in the English language (covering the UK, USA, Canada, Australia, New Zealand and Singapore).
The guidance has enjoyed widespread acclaim, covers 12 topics and has been adapted for use internationally with versions created for Bulgaria, China, France, Italy, Japan, and Turkey.
The evidence-based guidance now covers the following topics:
Benzodiazepines and Z-drugs (zopiclone and zolpidem)
Clozapine treatment
Digital technologies and telepsychiatry
Domestic violence and abuse
End of life care
Inpatient wards
Lithium treatment
Long-acting injectable (LAI) antipsychotics
Pregnancy and the perinatal period
Suicide and self-harm
Vaccine prioritisation and mental health
Vaccine uptake and vaccine hesitancy
The guidance has prompted discussions and publications on key areas relating to COVID-19 and mental health some of which are listed below. Visit our out media and publications page for a more complete list.
- Covid-19 and mental health: a transformational opportunity to apply an evidence-based approach to clinical practice and research
- COVID-19 and Telepsychiatry: Development of Evidence-Based Guidance for Clinicians
- COVID-19, mental health, and ethnic minorities
- COVID-19 vaccination prioritisation and mental health:
- COVID-19 vaccine hesitancy and mental health
